A novel approach to mitigate muscle atrophy in Guillain-Barre syndrome

© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

Abstract

Guillain-Barre syndrome (GBS) is the most common cause of acute paralytic neuropathy worldwide. GBS manifests as rapidly progressive, symmetrical numbness, paresthesia, and weakness secondary to either peripheral nerve demyelination or axonal loss. Despite effective disease modifying therapies (e.g., intravenous immunoglobulin) and individualized rehabilitation programs, many individuals recovering from GBS experience substantial muscle atrophy and incomplete recovery of strength with resultant long-term functional impairment. This narrative review explores the therapeutic potential of omega-3 fatty acid supplementation on enhancing recovery of people with GBS. This purported benefit may occur through several potential mechanisms, supported indirectly through studies using both experimental animal and clinical human models. These mechanisms include: (i) Anti-atrophic effects on skeletal muscle undergoing disuse and systemic inflammation; (ii) the use of omega-3s as a key building block comprising myelin; (iii) immune modulating effects optimizing conditions for remyelination; and (iv) preventing excitotoxic-like neuron death. The physiological mechanisms are explored in detail with examination of relevant clinical trials conducted to date. Through this exploration, there is sufficient support to justify future investigations directly examining the role omega-3 fatty acid supplementation may play as an adjunctive intervention that could have significant benefit at low cost and minimal risk of adverse events.

Keywords

Guillain-Barre syndrome

Fatty acids

Omega-3

Nutritional support

Muscular atrophy

Funding

None.

Conflict of interest

All authors deny any conflicts or competing interests with any institutes, organizations or agencies that might influence the integrity of results or objective interpretation of this submission.

References

[1]

Willison HJ, Jacobs BC, van Doorn PA, (2016), Guillain- Barré syndrome. Lancet, 388: 717–727. https://doi.org//10.1016/S0140-6736(16)00339-1

[2]

Shang P, Zhu M, Wang Y, et al., (2021), Axonal variants of Guillain-Barré syndrome: An update. J Neurol, 268: 2402–2419. https://doi.org//10.1007/s00415-020-09742-2

[3]

Pithadia AB, Kakadia N, (2010), Guillain-Barré syndrome (GBS). Pharmacol Rep, 62: 220–232. https://doi.org//10.1016/s1734-1140(10)70261-9

[4]

Mirian A, Nicolle MW, Budhram A, (2021), Guillain-Barré syndrome. Can Med Assoc J, 193: E378–E378. https://doi.org//10.1503/cmaj.202710

[5]

Florian IA, Lupan I, Sur L, et al., (2021), To be, or not to be… Guillain-Barré syndrome. Autoimmun Rev, 20: 102983. https://doi.org//10.1016/j.autrev.2021.102983

[6]

Fokke C, van den Berg B, Drenthen J, et al., (2014), Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain, 137: 33–43. https://doi.org//10.1093/BRAIN/AWT285

[7]

van den Berg B, Walgaard C, Drenthen J, et al., (2014), Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol, 10: 469–482. https://doi.org/10.1038/nrneurol.2014.121

[8]

Querol L, Lleixà C, (2021), Novel immunological and therapeutic insights in Guillain-Barré syndrome and CIDP. Neurotherapeutics, 18: 2222–2235. https://doi.org/10.1007/s13311-021-01117-3

[9]

Rajabally YA, Uncini A, (2012), Outcome and its predictors in Guillaine-Barré syndrome. J Neurol Neurosurg Psychiatry, 83: 711–718. https://doi.org/10.1136/jnnp-2011-301882

[10]

Harbo T, Markvardsen LK, Hellfritzsch MB, et al., (2019), Neuromuscular electrical stimulation in early rehabilitation of Guillain-Barré syndrome: A pilot study. Muscle Nerve, 59: 481–484. https://doi.org/10.1002/MUS.26396

[11]

Albers JW, Donofrio PD, McGonagle TK, (1985), Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve, 8: 528–539. https://doi.org/10.1002/MUS.880080609

[12]

Van Den Berg B, Storm EF, Garssen MJ, et al., (2018), Clinical outcome of Guillain-Barré syndrome after prolonged mechanical ventilation. J Neurol Neurosurg Psychiatry, 89: 949–954. https://doi.org/10.1136/JNNP-2018-317968

[13]

Ferguson EJ, Seigel JW, McGlory C, (2021), Omega-3 fatty acids and human skeletal muscle. Curr Opin Clin Nutr Metab Care, 24: 114–119. https://doi.org/10.1097/MCO.0000000000000723

[14]

Berciano J, (2021), Axonal degeneration in Guillain-Barré syndrome: A reappraisal. J Neurol, 268: 3728–3743. https://doi.org/10.1007/s00415-020-10034-y

[15]

Koike H, Fukami Y, Nishi R, et al., (2020), Ultrastructural mechanisms of macrophage-induced demyelination in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry, 91: 650–659. https://doi.org/10.1136/JNNP-2019-322479

[16]

Koike H, Katsuno M, (2021), Macrophages and autoantibodies in demyelinating diseases. Cells, 10: 844. https://doi.org//10.3390/cells10040844

[17]

Albert LJ, Inman RD, (1999), Molecular mimicry and autoimmunity. N Engl J Med, 341: 2068–2074. https://doi.org//10.1056/NEJM199912303412707

[18]

Koike H, Chiba A, Katsuno M, (2021), Emerging infection, vaccination, and Guillain-Barré syndrome: A review. Neurol Ther, 10: 523–537. https://doi.org/10.1007/s40120-021-00261-4

[19]

Laman JD, Huizinga R, Boons GJ, et al., (2022), Guillain- Barré syndrome: Expanding the concept of molecular mimicry. Trends Immunol, 43: 296–308. https://doi.org/10.1016/j.it.2022.02.003

[20]

Huizinga R, van den Berg B, van Rijs W, et al., (2015), Innate immunity to Campylobacter jejuni in Guillain-Barré syndrome. Ann Neurol, 78: 343–354. https://doi.org/10.1002/ANA.24442

[21]

Lleixà C, Martín-Aguilar L, Pascual-Goñi E, et al., (2021), Autoantibody screening in Guillain-Barré syndrome. J Neuroinflammation, 18: 251. https://doi.org/10.1186/s12974-021-02301-0

[22]

Van Den Berg B, Walgaard C, Drenthen J, et al., (2014), Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment and prognosis. Nat Publ Gr, 10: 469–482. https://doi.org/10.1038/nrneurol.2014.121

[23]

Kusunoki S, Kaida KI, Ueda M, (2008), Antibodies against gangliosides and ganglioside complexes in Guillain-Barré syndrome: New aspects of research. Biochim Biophys Acta, 1780: 441–444. https://doi.org/10.1016/j.bbagen.2007.10.001

[24]

Kuwabara S, Yuki N, (2013), Axonal Guillain-Barré syndrome: Concepts and controversies. Lancet Neurol, 12: 1180–1188. https://doi.org/10.1016/S1474-4422(13)70215-1

[25]

Hermans G, De Jonghe B, Bruyninckx F, et al., (2008), Clinical review: Critical illness polyneuropathy and myopathy. Crit Care, 12: 238. https://doi.org/10.1186/cc7100

[26]

Derde S, Hermans G, Derese I, et al., (2012), Muscle atrophy and preferential loss of myosin in prolonged critically ill patients. Crit Care Med, 40: 79–89. https://doi.org/10.1097/CCM.0b013e31822d7c18

[27]

Atherton PJ, Smith K, (2012), Muscle protein synthesis in response to nutrition and exercise. J Physiol, 590: 1049–1057. https://doi.org/10.1113/JPHYSIOL.2011.225003

[28]

Van Den Berghe G, (2016), On the neuroendocrinopathy of critical illness: Perspectives for feeding and novel treatments. Am J Respir Crit Care Med, 194: 1337–1348. https://doi.org/10.1164/rccm.201607-1516CI

[29]

Mitch WE, Goldberg AL, (1996), Mechanisms of muscle wasting-the role of the ubiquitin-proteasome pathway. N Engl J Med, 335: 1897–1905. https://doi.org/10.1056/NEJM199612193352507

[30]

Brink M, Anwar A, Delafontaine P, (2002), Neurohormonal factors in the development of catabolic/anabolic imbalance and cachexia. Int J Cardiol, 85: 111–121; discussion 121–124.

[31]

Cheung K, Rathbone A, Melanson M, et al., (2021), Pathophysiology and management of critical illness polyneuropathy and myopathy. J Appl Physiol (1985), 130: 1479–1489. https://doi.org/10.1152/japplphysiol.00019.2021

[32]

Powers SK, Kavazis AN, DeRuisseau KC, (2005), Mechanisms of disuse muscle atrophy: Role of oxidative stress. Am J Physiol Regul Integr Comp Physiol, 288: R337– R344. https://doi.org/10.1152/ajpregu.00469.2004

[33]

Grosu HB, Lee YI, Lee J, et al., (2012), Diaphragm muscle thinning in patients who are mechanically ventilated. Chest, 142: 1455–1460. https://doi.org/10.1378/CHEST.11-1638

[34]

Zambon M, Beccaria P, Matsuno J, et al., (2016), Mechanical ventilation and diaphragmatic atrophy in critically ill patients: An ultrasound study. Crit Care Med, 44: 1347–1352. https://doi.org/10.1097/CCM.0000000000001657

[35]

Bodine SC, Latres E, Baumhueter S, et al., (2001), Identification of ubiquitin ligases required for skeletal muscle atrophy. Science, 294: 1704–1708. https://doi.org/10.1126/SCIENCE.1065874

[36]

Kondo H, Miura M, Itokawa Y, (1993), Antioxidant enzyme systems in skeletal muscle atrophied by immobilization. Pflügers Arch, 422: 404–406. https://doi.org/10.1007/BF00374299

[37]

O’Loghlen A, Pérez-Morg/ado MI, Salinas M, et al., (2006), N-acetyl-cysteine abolishes hydrogen peroxide-induced modification of eukaryotic initiation factor 4F activity via distinct signalling pathways. Cell Signal, 18: 21–31. https://doi.org/10.1016/j.cellsig.2005.03.013

[38]

Powers SK, Smuder AJ, Criswell DS, (2011), Mechanistic links between oxidative stress and disuse muscle atrophy. Antioxid Redox Signal, 15: 2519–2528. https://doi.org/10.1089/ars.2011.3973

[39]

Appell HJ, Duarte JA, Soares JM, (1997), Supplementation of Vitamin E may attenuate skeletal muscle immobilization atrophy. Int J Sports Med, 18: 157–160. https://doi.org/10.1055/s-2007-972612

[40]

Ikemoto M, Nikawa T, Kano M, et al., (2002), Cysteine supplementation prevents unweighting-induced ubiquitination in association with redox regulation in rat skeletal muscle. Biol Chem, 383: 715–721. https://doi.org/10.1515/BC.2002.074

[41]

Betters JL, Criswell DS, Shanely RA, et al., (2004), Trolox attenuates mechanical ventilation-induced diaphragmatic dysfunction and proteolysis. Am J Respir Crit Care Med, 170: 1179–1184. https://doi.org/10.1164/rccm.200407-939OC

[42]

Ehmsen JT, Höke A, (2020), Cellular and molecular features of neurogenic skeletal muscle atrophy. Exp Neurol, 331: 113379. https://doi.org/10.1016/j.expneurol.2020.113379

[43]

Little BW, Barlow R, Perl DP, (1982), Denervation modulated changes in mouse skeletal muscle RNA concentration. Virchows Arch B Cell Pathol Incl Mol Pathol, 39: 1–7. https://doi.org/10.1007/BF02892831

[44]

Medina R, Wing SS, Goldberg AL, (1995), Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J, 307: 631–637. https://doi.org/10.1042/bj3070631

[45]

Wing SS, Haas AL, Goldberg AL, (1995), Increase in ubiquitin-protein conjugates concomitant with the increase in proteolysis in rat skeletal muscle during starvation and atrophy denervation. Biochem J, 307: 639–645. https://doi.org/10.1042/bj3070639

[46]

Medina R, Wing SS, Haas A, et al., (1991), Activation of the ubiquitin-ATP-dependent proteolytic system in skeletal muscle during fasting and denervation atrophy. Biomed Biochim Acta, 50: 347–356.

[47]

Shahar E, (2006), Current therapeutic options in severe Guillain-Barré syndrome. Clin Neuropharmacol, 29: 45–51. https://doi.org/10.1097/00002826-200601000-00011

[48]

Uncini A, Kuwabara S, (2018), The electrodiagnosis of Guillain-Barré syndrome subtypes: Where do we stand? Clin Neurophysiol, 129: 2586–2593. https://doi.org/10.1016/J.CLINPH.2018.09.025

[49]

Winer JB, Hughes RA, Osmond C, (1988), A prospective study of acute idiopathic neuropathy. I. Clinical features and their prognostic value. J Neurol Neurosurg Psychiatry, 51: 605–612. https://doi.org/10.1136/jnnp.51.5.605

[50]

Hughes RA, Swan AV, Raphaël JC, et al., (2007), Immunotherapy for Guillain-Barré syndrome: A systematic review. Brain, 130: 2245–2257. https://doi.org/10.1093/brain/awm004

[51]

Hughes RA, Wijdicks EF, Benson E, et al., (2005), Supportive care for patients with Guillain-Barré syndrome. Arch Neurol, 62: 1194–1198. https://doi.org/10.1001/archneur.62.8.1194

[52]

Wen P, Wang L, Liu H, et al., (2021), Risk factors for the severity of Guillain-Barré syndrome and predictors of short-term prognosis of severe Guillain-Barré syndrome. Sci Rep, 11: 11578. https://doi.org/10.1038/s41598-021-91132-3

[53]

Arsenault NS, Vincent PO, Yu BH, et al., (2016), Influence of exercise on patients with Guillain-Barré syndrome: A systematic review. Physiother Can, 68: 367–376. https://doi.org/10.3138/PTC.2015-58

[54]

Khan F, Pallant JF, Amatya B, et al., (2011), Outcomes of high- and low-intensity rehabilitation programme for persons in chronic phase after guillain-barré syndrome: A randomized controlled trial. J Rehabil Med, 43: 638–646. https://doi.org/10.2340/16501977-0826

[55]

Bensman A, (1970), Strenuous exercise may impair muscle function in Guillain-Barre patients. JAMA, 214: 468–469.

[56]

Meythaler JM, DeVivo MJ, Braswell WC, (1997), Rehabilitation outcomes of patients who have developed Guillain-Barreé syndrome. Am J Phys Med Rehabil, 76: 411–419. https://doi.org/10.1097/00002060-199709000-00012

[57]

Saini RK, Keum YS, (2018), Omega-3 and omega-6 polyunsaturated fatty acids: Dietary sources, metabolism, and significance-A review. Life Sci, 203: 255–267. https://doi.org/10.1016/J.LFS.2018.04.049

[58]

Calder PC, (2017), Omega-3 fatty acids and inflammatory processes: From molecules to man. Biochem Soc Trans, 45: 1105–1115. https://doi.org/10.1042/BST20160474

[59]

Covington MB, (2004), Omega-3 fatty acids. Am Fam Physician, 70: 133–140.

[60]

McGlory C, Calder PC, Nunes EA, (2019), The influence of omega-3 fatty acids on skeletal muscle protein turnover in health, disuse, and disease. Front Nutr, 6: 144. https://doi.org/10.3389/fnut.2019.00144

[61]

Arterburn LM, Hall EB, Oken H, (2006), Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr, 83 Suppl 6: 1467S–1476S. https://doi.org/10.1093/AJCN/83.6.1467S

[62]

National Institutes of Health, (2022), Omega-3 Fatty Acids-Health Professional Fact Sheet. Maryland: National Institutes of Health.

[63]

Mcglory C, Gorissen SH, Kamal M, et al., (2019), Omega‐3 fatty acid supplementation attenuates skeletal muscle disuse atrophy during two weeks of unilateral leg immobilization in healthy young women. FASEB J, 33: 4586–4597. https://doi.org/10.1096/fj.201801857RRR

[64]

Murphy RA, Mourtzakis M, Chu QS, et al., (2010), Skeletal muscle depletion is associated with reduced plasma (n-3) fatty acids in non-small cell lung cancer patients. J Nutr, 140: 1602–1606. https://doi.org/10.3945/JN.110.123521

[65]

dos Reis AS, Limirio LS, Santos HO, et al., (2021), Intake of polyunsaturated fatty acids and ω-3 are protective factors for sarcopenia in kidney transplant patients. Nutrition, 81: 110929. https://doi.org/10.1016/j.nut.2020.110929

[66]

Ryan AM, Reynolds JV, Healy L, et al., (2009), Enteral nutrition enriched with eicosapentaenoic acid (EPA) preserves lean body mass following esophageal cancer surgery: Results of a double-blinded randomized controlled trial. Ann Surg, 249: 355–363. https://doi.org/10.1097/SLA.0b013e31819a4789

[67]

Smith GI, Atherton P, Reeds DN, et al., (2011), Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: A randomized controlled trial. Am J Clin Nutr, 93: 402–412. https://doi.org/10.3945/ajcn.110.005611

[68]

Smith GI, Julliand S, Reeds DN, et al., (2015), Fish oil–derived n-3 PUFA therapy increases muscle mass and function in healthy older adults. Am J Clin Nutr, 102: 115–122. https://doi.org/10.3945/AJCN.114.105833

[69]

Ter Borg S, Luiking YC, van Helvoort A, et al., (2019), Low levels of branched chain amino acids, eicosapentaenoic acid and micronutrients are associated with low muscle mass, strength and function in community-dwelling older adults. J Nutr Health Aging, 23: 27–34. https://doi.org/10.1007/s12603-018-1108-3

[70]

Huang YH, Chiu WC, Hsu YP, et al., (2020), Effects of omega-3 fatty acids on muscle mass, muscle strength and muscle performance among the elderly: A meta-analysis. Nutrients, 12: 3739. https://doi.org/10.3390/NU12123739

[71]

Jang IY, Jung HW, Park JH, et al., (2020), Lower serum n-3 fatty acid level in older adults with sarcopenia. Nutrients, 12: 2959. https://doi.org/10.3390/nu12102959

[72]

Boutry-Regard C, Vinyes-Parés G, Breuillé D, et al., (2020), Supplementation with whey protein, omega-3 fatty acids and polyphenols combined with electrical muscle stimulation increases muscle strength in elderly adults with limited mobility: A randomized controlled trial. Nutrients, 12: 1866. https://doi.org/10.3390/nu12061866

[73]

Crossland H, Skirrow S, Puthucheary ZA, et al., (2019), The impact of immobilisation and inflammation on the regulation of muscle mass and insulin resistance: Different routes to similar end-points. J Physiol, 597: 1259–1270. https://doi.org/10.1113/JP275444

[74]

Calder PC, (2015), Marine omega-3 fatty acids and inflammatory processes: Effects, mechanisms and clinical relevance. Biochim Biophys Acta, 1851: 469–484. https://doi.org/10.1016/J.BBALIP.2014.08.010

[75]

Wada M, DeLong CJ, Hong YH, et al., (2007), Enzymes and receptors of prostaglandin pathways with arachidonic acid-derived versus eicosapentaenoic acid-derived substrates and products. J Biol Chem, 282: 22254–22266. https://doi.org/10.1074/JBC.M703169200

[76]

Miotto PM, Mcglory C, Bahniwal R, et al., (2019), Supplementation with dietary ω-3 mitigates immobilization-induced reductions in skeletal muscle mitochondrial respiration in young women. FASEB J, 33: 8232–8240. https://doi.org/10.1096/fj.201900095R

[77]

Salvati S, Natali F, Attorri L, et al., (2008), Eicosapentaenoic acid stimulates the expression of myelin proteins in rat brain. J Neurosci Res, 86: 776–784. https://doi.org/10.1002/jnr.21537

[78]

Siegert E, Paul F, Rothe M, et al., (2017), The effect of omega–3 fatty acids on central nervous system remyelination in fat-1 mice. BMC Neurosci, 18: 19. https://doi.org/10.1186/S12868-016-0312-5

[79]

Weylandt KH, Krause LF, Gomolka B, et al., (2011), Suppressed liver tumorigenesis in fat-1 mice with elevated omega-3 fatty acids is associated with increased omega-3 derived lipid mediators and reduced TNF-α. Carcinogenesis, 32: 897–903. https://doi.org/10.1093/carcin/bgr049

[80]

Peters BD, Machielsen MW, Hoen WP, et al., (2013), Polyunsaturated fatty acid concentration predicts myelin integrity in early-phase psychosis. Schizophr Bull, 39: 830–838. https://doi.org/10.1093/schbul/sbs089

[81]

Bourre JM, Pascal G, Durand G, et al., (1984), Alterations in the fatty acid composition of rat brain cells (neurons, astrocytes, and oligodendrocytes) and of subcellular fractions (myelin and synaptosomes) induced by a diet devoid of n‐3 fatty acids. J Neurochem, 43: 342–348. https://doi.org/10.1111/j.1471-4159.1984.tb00906.x

[82]

Tatsumi Y, Kato A, Sango K, et al., (2019), Omega-3 polyunsaturated fatty acids exert anti-oxidant effects through the nuclear factor (erythroid-derived 2)-related factor 2 pathway in immortalized mouse Schwann cells. J Diabetes Investig, 10: 602–612. https://doi.org/10.1111/jdi.12931

[83]

Doble A, (1999), The role of excitotoxicity in neurodegenerative disease: Implications for therapy. Pharmacol Ther, 81: 163–221.

[84]

Michael-Titus AT, (2007), Omega-3 fatty acids and neurological injury. Prostaglandins Leukot Essent Fat Acids, 77: 295–300. https://doi.org/10.1016/j.plefa.2007.10.021

[85]

Wang X, Zhao X, Mao ZY, et al., (2003), Neuroprotective effect of docosahexaenoic acid on glutamate-induced cytotoxicity in rat hippocampal cultures. Neuroreport, 14: 395–401. https://doi.org/10.1097/00001756-200312190-00033

[86]

Puthucheary ZA, Rawal J, McPhail M, et al., (2013), Acute skeletal muscle wasting in critical illness. JAMA, 310: 1591–1600. https://doi.org/10.1001/jama.2013.278481

[87]

Abu-Rumeileh S, Abdelhak A, Foschi M, et al., (2021), Guillain-Barré syndrome spectrum associated with COVID-19: An up-to-date systematic review of 73 cases. J Neurol, 268: 1133–1170. https://doi.org/10.1007/s00415-020-10124-x

[88]

Zhang AC, De Silva ME, MacIsaac RJ, et al., (2020), Omega-3 polyunsaturated fatty acid oral supplements for improving peripheral nerve health: A systematic review and meta-analysis. Nutr Rev, 78: 323–341. https://doi.org/10.1093/nutrit/nuz054

Previous article in this issue

Next article in this issue

Advanced Neurology, Electronic ISSN: 2810-9619 Print ISSN: 3060-8589, Published by AccScience Publishing